488 related articles for article (PubMed ID: 23481700)
1. The human leukocyte antigen-presented ligandome of B lymphocytes.
Hassan C; Kester MG; de Ru AH; Hombrink P; Drijfhout JW; Nijveen H; Leunissen JA; Heemskerk MH; Falkenburg JH; van Veelen PA
Mol Cell Proteomics; 2013 Jul; 12(7):1829-43. PubMed ID: 23481700
[TBL] [Abstract][Full Text] [Related]
2. Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity.
Mommen GP; Marino F; Meiring HD; Poelen MC; van Gaans-van den Brink JA; Mohammed S; Heck AJ; van Els CA
Mol Cell Proteomics; 2016 Apr; 15(4):1412-23. PubMed ID: 26764012
[TBL] [Abstract][Full Text] [Related]
3. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry.
Lorente E; Marcilla M; de la Sota PG; Quijada-Freire A; Mir C; López D
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638844
[TBL] [Abstract][Full Text] [Related]
4. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
[TBL] [Abstract][Full Text] [Related]
6. Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.
Mylonas R; Beer I; Iseli C; Chong C; Pak HS; Gfeller D; Coukos G; Xenarios I; Müller M; Bassani-Sternberg M
Mol Cell Proteomics; 2018 Dec; 17(12):2347-2357. PubMed ID: 30171158
[TBL] [Abstract][Full Text] [Related]
7. The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes.
Bremers AJ; van der Burg SH; Kuppen PJ; Kast WM; van de Velde CJ; Melief CJ
J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):77-85. PubMed ID: 8574469
[TBL] [Abstract][Full Text] [Related]
8. Tumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles.
Kumar P; Boyne C; Brown S; Qureshi A; Thorpe P; Synowsky SA; Shirran S; Powis SJ
Immunology; 2022 Jun; 166(2):249-264. PubMed ID: 35318648
[TBL] [Abstract][Full Text] [Related]
9. Pre-fractionation Extends but also Creates a Bias in the Detectable HLA Class Ι Ligandome.
Demmers LC; Heck AJR; Wu W
J Proteome Res; 2019 Apr; 18(4):1634-1643. PubMed ID: 30784271
[TBL] [Abstract][Full Text] [Related]
10. Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.
Löffler MW; Kowalewski DJ; Backert L; Bernhardt J; Adam P; Schuster H; Dengler F; Backes D; Kopp HG; Beckert S; Wagner S; Königsrainer I; Kohlbacher O; Kanz L; Königsrainer A; Rammensee HG; Stevanović S; Haen SP
Cancer Res; 2018 Aug; 78(16):4627-4641. PubMed ID: 29789417
[TBL] [Abstract][Full Text] [Related]
11. Generating data for databases--the peptide repertoire of HLA molecules.
Stevanović S; Lemmel C; Häntschel M; Eberle U
Novartis Found Symp; 2003; 254():143-55; discussion 155-64, 216-22, 250-2. PubMed ID: 14712936
[TBL] [Abstract][Full Text] [Related]
12. The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.
Gfeller D; Guillaume P; Michaux J; Pak HS; Daniel RT; Racle J; Coukos G; Bassani-Sternberg M
J Immunol; 2018 Dec; 201(12):3705-3716. PubMed ID: 30429286
[TBL] [Abstract][Full Text] [Related]
13. High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.
Chong C; Marino F; Pak H; Racle J; Daniel RT; Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
Mol Cell Proteomics; 2018 Mar; 17(3):533-548. PubMed ID: 29242379
[TBL] [Abstract][Full Text] [Related]
14. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling.
Meyer VS; Kastenmuller W; Gasteiger G; Franz-Wachtel M; Lamkemeyer T; Rammensee HG; Stevanovic S; Sigurdardottir D; Drexler I
J Immunol; 2008 Nov; 181(9):6371-83. PubMed ID: 18941228
[TBL] [Abstract][Full Text] [Related]
15. HLA Class II Presentation Is Specifically Altered at Elevated Temperatures in the B-Lymphoblastic Cell Line JY.
Demmers LC; Wu W; Heck AJR
Mol Cell Proteomics; 2021; 20():100089. PubMed ID: 33933681
[TBL] [Abstract][Full Text] [Related]
16. Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications.
Sidney J; Vela JL; Friedrich D; Kolla R; von Herrath M; Wesley JD; Sette A
BMC Immunol; 2018 Mar; 19(1):12. PubMed ID: 29562882
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.
Kowalewski DJ; Walz S; Backert L; Schuster H; Kohlbacher O; Weisel K; Rittig SM; Kanz L; Salih HR; Rammensee HG; Stevanović S; Stickel JS
Blood Cancer J; 2016 Apr; 6(4):e411. PubMed ID: 27058226
[TBL] [Abstract][Full Text] [Related]
18. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
Bilich T; Nelde A; Bichmann L; Roerden M; Salih HR; Kowalewski DJ; Schuster H; Tsou CC; Marcu A; Neidert MC; Lübke M; Rieth J; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Bauer J; Märklin M; Peper JK; Klein R; Kohlbacher O; Kanz L; Rammensee HG; Stevanović S; Walz JS
Blood; 2019 Feb; 133(6):550-565. PubMed ID: 30530751
[TBL] [Abstract][Full Text] [Related]
19. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules.
Daniel S; Brusic V; Caillat-Zucman S; Petrovsky N; Harrison L; Riganelli D; Sinigaglia F; Gallazzi F; Hammer J; van Endert PM
J Immunol; 1998 Jul; 161(2):617-24. PubMed ID: 9670935
[TBL] [Abstract][Full Text] [Related]
20. The HLA Ligandome Comprises a Limited Repertoire of O-GlcNAcylated Antigens Preferentially Associated With HLA-B*07:02.
Mukherjee S; Sanchez-Bernabeu A; Demmers LC; Wu W; Heck AJR
Front Immunol; 2021; 12():796584. PubMed ID: 34925382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
